Phibro Animal Health Corporation Class A (PAHC) Stock Price

PAHCStock

$38.82+0.65%52W

Market Cap$1.58B

P/E15.81x

PEG Ratio1.68

Div yield4.55%

Beta0.42

PAHC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-44.13%

Price vs S&P 500 (4W)13.26%

PEG Ratio1.68

VGM Score60.81

P/E Ratio (Annual)15.81x

Indicated Dividend Yield (Annual)4.55%

P/CF (Annual)22.86x

Book Value / Share (Quarterly)$9.50

P/TBV (Annual)3.58x

Indicated Dividend (Annual)$0.48

Revenue Growth (3Y)15.79%

Cash Flow / Share (Quarterly)$0.24

Payout Ratio (TTM)19.52%

Price vs S&P 500 (YTD)-8.02%

Gross Margin (TTM)33.33%

Net Profit Margin (TTM)6.57%

EPS (TTM)$2.43

10-Day Avg Trading Volume0.24M

EPS Excl Extra (TTM)$2.43

Revenue Growth (5Y)12.74%

EPS (Annual)$2.43

Dividend / Share (Annual)$0.48

ROI (Annual)8.92%

Gross Margin (Annual)33.33%

Net Profit Margin (5Y Avg)3.82%

Cash / Share (Quarterly)$2.02

P/E Basic Excl Extra (TTM)15.81x

Revenue Growth QoQ (YoY)4.77%

EPS Growth (5Y)12.63%

P/E Normalized (Annual)15.81x

ROA (Last FY)6.64%

Revenue Growth TTM (YoY)17.12%

EBITD / Share (TTM)$6.00

ROE (5Y Avg)14.80%

Operating Margin (TTM)12.81%

Cash Flow / Share (Annual)$0.24

P/B Ratio4.09x

P/B Ratio (Quarterly)3.30x

Net Income / Employee (Annual)$40,300

EV / Revenue (TTM)1.48x

Net Interest Coverage (TTM)3.41x

ROA (TTM)6.95%

EPS Growth QoQ (YoY)25.19%

EV / EBITDA (TTM)9.14x

EPS Incl Extra (Annual)$2.43

Current Ratio (Annual)2.96x

Quick Ratio (Quarterly)1.27x

3-Month Avg Trading Volume0.25M

52-Week Price Return0.65%

EV / Free Cash Flow (Annual)227.81x

P/E Incl Extra (TTM)15.81x

Revenue / Employee (TTM)$613,400

Tangible BV / Share (Quarterly)$8.76

P/S Ratio (Annual)1.04x

Asset Turnover (Annual)1.01x

52-Week High$60.08

Operating Margin (5Y Avg)8.46%

EPS Excl Extra (Annual)$2.43

CapEx CAGR (5Y)15.04%

Tangible BV CAGR (5Y)15.07%

26-Week Price Return-34.23%

Quick Ratio (Annual)1.27x

13-Week Price Return16.54%

Total Debt / Equity (Annual)1.90x

Current Ratio (Quarterly)2.96x

Enterprise Value$2.25B

Revenue / Share Growth (5Y)12.49%

Asset Turnover (TTM)1.06x

Book Value / Share Growth (5Y)10.04%

Revenue / Employee (Annual)$613,400

Inventory Turnover (Annual)2.07x

Pretax Margin (Annual)9.05%

Cash / Share (Annual)$2.02

3-Month Return Std Dev31.64%

Gross Margin (5Y Avg)31.30%

Net Income / Employee (TTM)$40,300

EBITDA CAGR (5Y)18.15%

EBITDA Interim CAGR (5Y)17.85%

ROE (Last FY)25.87%

Net Interest Coverage (Annual)3.41x

EPS Basic Excl Extra (Annual)$2.43

P/FCF (TTM)109.68x

Receivables Turnover (TTM)6.50x

EV / Free Cash Flow (TTM)227.81x

Total Debt / Equity (Quarterly)1.90x

EPS Incl Extra (TTM)$2.43

Receivables Turnover (Annual)6.50x

ROI (TTM)9.20%

Dividend Growth Rate (5Y)0.01%

P/S Ratio (TTM)1.04x

Pretax Margin (5Y Avg)5.71%

Revenue / Share (Annual)$37.06

Tangible BV / Share (Annual)$8.76

Forward P/E9.86x

Free OCF CAGR (5Y)-12.28%

Price vs S&P 500 (52W)-14.88%

P/E Ratio (TTM)15.81x

EPS Growth TTM (YoY)105.25%

Year-to-Date Return3.91%

5-Day Price Return3.71%

EPS Normalized (Annual)$2.43

ROA (5Y Avg)3.82%

Net Profit Margin (Annual)6.57%

Month-to-Date Return8.62%

Cash Flow / Share (TTM)$1.36

EBITD / Share (Annual)$6.00

EPS Growth (3Y)44.61%

Operating Margin (Annual)12.81%

LT Debt / Equity (Annual)1.84x

P/CF (TTM)22.86x

ROI (5Y Avg)5.09%

P/E Excl Extra (TTM)15.81x

LT Debt / Equity (Quarterly)1.84x

EPS Basic Excl Extra (TTM)$2.43

P/TBV (Quarterly)3.58x

Payout Ratio (Annual)19.52%

P/B Ratio (Annual)3.30x

Dividend / Share (TTM)$0.48

Inventory Turnover (TTM)2.07x

Pretax Margin (TTM)9.05%

Book Value / Share (Annual)$9.50

Price vs S&P 500 (13W)13.86%

Net Margin Growth (5Y)0.12%

Dividend Yield (TTM)1.23%

Beta0.42x

P/FCF (Annual)159.76x

Revenue / Share (TTM)$37.04

ROE (TTM)28.67%

52-Week Low$28.25

vGradeC

gGradeB

mGradeB

vgmGradeB

PAHC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 26, 2026	$0.73	$0.85	+17.08%(+$0.12)
Q1 2026	May 6, 2026	$0.71	$0.76	+6.52%(+$0.05)
Q4 2025	Feb 4, 2026	$0.67	$0.87	+29.85%(+$0.20)
Q3 2025	Nov 5, 2025	$0.60	$0.73	+21.09%(+$0.13)
Q2 2025	Aug 27, 2025	$0.52	$0.57	+9.35%(+$0.05)

PAHC Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

2.50

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PAHCPhibro Animal Health Corporation Class A	C	B	B	1.0x	17.1%	33.3%	12.6%	$38.82
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Phibro Animal Health Corporation Class A

Phibro Animal Health Corp provides diversified animal health and mineral nutrition products for food-producing animals including poultry, swine, beef cattle, dairy cattle, and aquaculture. The company manufactures and markets antibacterials, anticoccidials, vaccines, and specialty nutritional products through three segments: Animal Health (its primary revenue driver), Mineral Nutrition, and Performance Products. The company operates in the United States and international markets.